Skip to main content

Kyle Mixon

Analyst

Canaccord Genuity

Equibles does not estimate personal net worth.

About Kyle Mixon

Kyle Mixon is recorded as Analyst at Canaccord Genuity. Kyle Mixon has spoken on 13 earnings calls and 5 other investor events across 11 companies, most recently for Guardant Health, Inc. on August 12, 2026. Those appearances were for Exagen Inc. (XGN), GeneDx Holdings Corp. (WGS), GRAIL, Inc. (GRAL), Caris Life Sciences, Inc. (CAI), Quantum-Si Inc (QSI) and 6 other companies. The companies whose calls Kyle Mixon spoke on are classified in the Healthcare sector.

Kyle Mixon on recent calls

“I cover life science, tools, and diagnostics for Canaccord. Really pleased to welcome you to a fireside chat with Garden Health here with us today. The company is a leader in precision oncology diagnostics across screening, MRD, and therapy selection.”
Analyst — Canaccord Genuity, Canaccord Genuity 46th Annual Growth Conference ·
“I cover life-sensuals and diagnostics with Canaccord. Pleased to have Natera here with us for a far-sight chat. With the company, we have Mike Brophy, CFO. And just for background, Natera is a leading provider of self-having DNA-based testing for women's health oncology and organ health.”
Analyst — Canaccord Genuity, Canaccord Genuity 46th Annual Growth Conference ·
“I cover life science, tools, and diagnostics for Canaccord. Please welcome you to a fireside chat with Grail here with us today. The company offers the first of its kind commercialized multi-cancer early detection test called Gallery.”
Analyst — Canaccord Genuity, Canaccord Genuity 46th Annual Growth Conference ·
“I cover lifestyle solutions and diagnostics for Canaccord. I'm pleased to welcome you to a fireside chat with Exogen here with us today. Exogen is a pure play leading provider of autoimmune disease testing products and we'll learn more about that today with the current focus in lupus expanding.”
Analyst — Canaccord Genuity, Canaccord Genuity Growth Conference ·
“I cover Lifestyle and Sewells and Diagnostics for Canaccord. Please welcome you to a fireside chat with Lucid Diagnostics. The company offers the first of its kind diagnostic test for a pre-cancer to estival genital cancer called Baird Esophagus.”
Analyst — Canaccord Genuity, Canaccord Genuity 46th Annual Growth Conference ·

Affiliation history

  • Canaccord Genuity

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity

Show 6 earlier activities